“BioNTech”) andDuality Biologics(Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patien...
33. Zhang, Y., et al., Anti-inflammatory compound and use thereof. 2023, Duality Biologics (Suzhou) Co., Ltd. 34. Hua, H., The Era Post DS8201: Opportunities and challenges, in The 8th Biocytogen Model Animals...
30, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio, securing global development, manufacturing, and commercialization ...
Juni 2024 –BioNTech SE (Nasdaq: BNTX, „BioNTech“) und Duality Biologics (Suzhou) Co., Ltd. („DualityBio“) gaben heute bekannt, dass die amerikanische Arzneimittelbehörde (U.S. Food and Drug Admin...
Mainz and Shanghai (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next ...
BioNTech SE and Duality Biologics Co., Ltd. announced that the FDA granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer (“CRPC”) who ...
BioNTech SE and Duality Biologics Co. Ltd. announced that the companies have entered into exclusive license and collaboration agreements for two ADC assets to develop, manufacture and commercialize the two assets glo...